A Study Evaluating Monthly (Every 4 Weeks) Dosing of Atacicept in Patients with IgAN

Status

Recruiting

Phases

Phase 2

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2025-521519-37-00

Acronym

VT-001-0020

Enrollment

Registered

2025-09-24

Start date

2025-10-10

Completion date

Unknown

Last updated

2025-09-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

IgA Nephropathy (IgAN); Berger Disease; Renal and Urinary Disorders

Brief summary

Gd-IgA1 levels through Week 24

Detailed description

Incidence of treatment-emergent adverse events, and changes from baseline in routine laboratory and vital sign parameters, IgG, IgM, and IgA levels through Week 24, Serum concentration of atacicept through the end of study, Anti-drug antibody status through the end of study, UPCR values through the end of study

Interventions

DRUGAtacicept

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Design outcomes

Primary

Measure	Time frame
Gd-IgA1 levels through Week 24	—

Secondary

Measure	Time frame
Incidence of treatment-emergent adverse events, and changes from baseline in routine laboratory and vital sign parameters, IgG, IgM, and IgA levels through Week 24, Serum concentration of atacicept through the end of study, Anti-drug antibody status through the end of study, UPCR values through the end of study	—

Countries

Poland, Spain

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026